Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival. As a standard, surgery is usually followed by adjuvant therapy that improves survival but neoadjuvant therapy (NAT) is a rapidly emerging concept that needs to be explored and validated in terms of therapeutic options in borderline resectable pancreatic tumors. In this setting, preoperative FFX seems to be feasible and can be prolonged by radiation therapy. However, the exact and best therapeutic sequence is not yet known a

Trial Details

NCT ID
NCT05083247
Phase
PHASE2
Sponsor
Erasme University Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • mFOLFIRINOX or Gemcitabine nab-paclitaxel
  • Isotoxic High-Dose (iHD)-SBRT
  • Surgery
Locations (sample)
  • Antwerp, Belgium|51.22047,4.40026
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878
  • Brussels, Belgium|50.85045,4.34878

Key Eligibility Criteria

  • Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinated process or body or tail. Diagnosis should be verified by local …
  • cTNM stage: T1-4N0-2M0
  • Confirmation of clinical and radiographic stage as borderline resectable (CT scan and/or MRI scan with contrast according to the NCCN criteria) by …
  • Age \> 18 years old

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →